Big Move For Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ) soared at $6.61, a gain of 48.8%. On Fri, Apr 10, 2026, ZNTL:NASDAQ touched a New 2-Week High of $6.61. The stock appeared on our News Catalysts scanner on Thu, Apr 09, 2026 at 10:13 AM in the 'BIOTECH' category. From Fri, Mar 27, 2026, the stock recorded 88.89% Up Days and 60.00% Green Days

About Zentalis Pharmaceuticals, Inc. (ZNTL:NASDAQ)

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company's product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.